Immune Thrombocytopenic Purpura | Treatment Algorithms: Claims Data Analysis | US | 2025

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided into immunomodulators, thrombopoietin-receptor agonists (TPO-RAs), and spleen tyrosine kinase inhibitors (Syk inhibitors). Systemic glucocorticoids and TPO-RAs are the pillars of clinical management; however, alternative therapies such fostamatinib (Rigel Pharmaceuticals’ Syk inhibitor Tavalisse) and rituximab provide additional options for refractory disease. This report offers insight from U.S. real-world claims data into current prescribing trends in ITP to help new players better understand current treatment practices in ITP that may help define the market niche for their emerging product.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed immune thrombocytopenic purpura patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed immune thrombocytopenic purpura patients?
• How have TPO-RAs and fostamatinib been integrated into the treatment algorithm, and what is its source of business? ·
• What percentage of immune thrombocytopenic purpura patients receive drug therapy within January 2025 – March 2025 of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within January 2025 – March 2025 of diagnosis? ·
• What percentage of immune thrombocytopenic purpura patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations? ·
• What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Geography: United States

Real-world data: Patient-level claims data analysis

Key drugs covered: TPO-RAs, Syk inhibitors, glucocorticoids, immunostimulants, immunosuppressants

Key analyses:

• Brand / therapy usage across longitudinal patient sample
• Newly diagnosed patient analysis
• Treatment initiation and progression
• Line of therapy analysis
• Combination therapy analysis
• Source of business for recently treated patients
• Persistency and compliance analysis
• Product-level patient flow charts

Key features: Dashboard featuring interactive visuals, easy navigation, and expanded analyses